Nilofer Saba Azad, MD, discusses selecting between regorafenib and TAS-102 in colorectal cancer.
Nilofer Saba Azad, MD
Advertisement
Articles by Nilofer Saba Azad, MD
Nilofer Saba Azad, MD, discusses third-line treatment options for patients with colorectal cancer.
Nilofer Saba Azad, MD, discusses future research efforts in colorectal cancer.
Nilofer Saba Azad, MD, discusses the significance of germline testing in colorectal cancer.
Nilofer Saba Azad, MD, discusses treatment considerations in right- versus left-sided colorectal cancer.
Nilofer Saba Azad, MD, discusses remaining challenges in colorectal cancer.
Advertisement
Latest Updated Articles
Dr. Azad on Treatment Considerations in Right- Versus Left-Sided CRCPublished: October 16th 2020 | Updated:
Dr. Azad on the Importance of Germline Testing in CRCPublished: October 19th 2020 | Updated:
Dr. Azad on Future Research Efforts in CRCPublished: October 21st 2020 | Updated:
Dr. Azad on Selecting Between Regorafenib and TAS-102 in CRCPublished: October 30th 2020 | Updated:
Dr. Azad on Remaining Challenges in CRCPublished: October 15th 2020 | Updated:
Dr. Azad on Third-Line Treatment Options in CRCPublished: October 29th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
4
Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma
5